Cargando…
Aldehyde dehydrogenase 2 polymorphism is associated with chemotherapy‐related cognitive impairment in patients with breast cancer who receive chemotherapy
BACKGROUND: Chemotherapy‐related cognitive impairment (CRCI) is a common but easily overlooked condition that markedly affects the quality of life (QOL) of patients with breast cancer. The rs671 is a common gene polymorphism of aldehyde dehydrogenase 2 (ALDH2) in Asia that is involved in aldehyde me...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028021/ https://www.ncbi.nlm.nih.gov/pubmed/36200595 http://dx.doi.org/10.1002/cam4.5319 |
_version_ | 1784909844546846720 |
---|---|
author | Yao, Senbang Li, Wen Liu, Shaochun Cai, Yinlian Zhang, Qianqian Tang, Lingxue Yu, Sheng Jing, Yanyan Yin, Xiangxiang Cheng, Huaidong |
author_facet | Yao, Senbang Li, Wen Liu, Shaochun Cai, Yinlian Zhang, Qianqian Tang, Lingxue Yu, Sheng Jing, Yanyan Yin, Xiangxiang Cheng, Huaidong |
author_sort | Yao, Senbang |
collection | PubMed |
description | BACKGROUND: Chemotherapy‐related cognitive impairment (CRCI) is a common but easily overlooked condition that markedly affects the quality of life (QOL) of patients with breast cancer. The rs671 is a common gene polymorphism of aldehyde dehydrogenase 2 (ALDH2) in Asia that is involved in aldehyde metabolism and may be closely related to CRCI. However, no study has yet summarised the association between ALDH2 and CRCI. METHODS: This study enrolled one hundred and twenty‐four patients diagnosed with breast cancer according to the pathology results, genotyped for ALDH2 single‐nucleotide polymorphisms (SNP) to explore these. The mini‐mental state exam (MMSE), verbal fluency test (VFT), and digit span test (DST) results were compared in these patients before and after chemotherapy (CT). RESULTS: We found that patients with ALDH2 gene genotypes of rs671_GG, rs886205_GG, rs4648328_CC, and rs4767944_TT polymorphisms were more likely to suffer from cognitive impairment during chemotherapy. A trend toward statistical significance was observed for rs671_GG of DST (z = 2.769, p = 0.006), VFT (t = 4.624, P<0.001); rs886205_GG of DST (z = 3.663, P<0.001); rs4648328_CC of DST (z = 2.850, p = 0.004), VFT (t = 3.477, p = 0.001); and rs4767944_TT of DST (z = 2.967, p = 0.003), VFT (t = 2.776, p = 0.008). The cognitive indicators of these patients significantly decreased after chemotherapy (p < 0.05). The difference in ALDH2 rs671 was most obvious. CONCLUSION: Our results showed what kinds of ALDH2 genotyped patients that are more likely to develop CRCI. In the future, it may be possible to infer the risk of CRCI by detecting the single‐nucleotide locus of ALDH2 that is conducive to strengthening clinical interventions for these patients and improving their QOL. More importantly, this study has important implications for Asian women with breast cancer as ALDH2 rs671 is a common polymorphism in Asians. |
format | Online Article Text |
id | pubmed-10028021 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100280212023-03-22 Aldehyde dehydrogenase 2 polymorphism is associated with chemotherapy‐related cognitive impairment in patients with breast cancer who receive chemotherapy Yao, Senbang Li, Wen Liu, Shaochun Cai, Yinlian Zhang, Qianqian Tang, Lingxue Yu, Sheng Jing, Yanyan Yin, Xiangxiang Cheng, Huaidong Cancer Med RESEARCH ARTICLES BACKGROUND: Chemotherapy‐related cognitive impairment (CRCI) is a common but easily overlooked condition that markedly affects the quality of life (QOL) of patients with breast cancer. The rs671 is a common gene polymorphism of aldehyde dehydrogenase 2 (ALDH2) in Asia that is involved in aldehyde metabolism and may be closely related to CRCI. However, no study has yet summarised the association between ALDH2 and CRCI. METHODS: This study enrolled one hundred and twenty‐four patients diagnosed with breast cancer according to the pathology results, genotyped for ALDH2 single‐nucleotide polymorphisms (SNP) to explore these. The mini‐mental state exam (MMSE), verbal fluency test (VFT), and digit span test (DST) results were compared in these patients before and after chemotherapy (CT). RESULTS: We found that patients with ALDH2 gene genotypes of rs671_GG, rs886205_GG, rs4648328_CC, and rs4767944_TT polymorphisms were more likely to suffer from cognitive impairment during chemotherapy. A trend toward statistical significance was observed for rs671_GG of DST (z = 2.769, p = 0.006), VFT (t = 4.624, P<0.001); rs886205_GG of DST (z = 3.663, P<0.001); rs4648328_CC of DST (z = 2.850, p = 0.004), VFT (t = 3.477, p = 0.001); and rs4767944_TT of DST (z = 2.967, p = 0.003), VFT (t = 2.776, p = 0.008). The cognitive indicators of these patients significantly decreased after chemotherapy (p < 0.05). The difference in ALDH2 rs671 was most obvious. CONCLUSION: Our results showed what kinds of ALDH2 genotyped patients that are more likely to develop CRCI. In the future, it may be possible to infer the risk of CRCI by detecting the single‐nucleotide locus of ALDH2 that is conducive to strengthening clinical interventions for these patients and improving their QOL. More importantly, this study has important implications for Asian women with breast cancer as ALDH2 rs671 is a common polymorphism in Asians. John Wiley and Sons Inc. 2022-10-06 /pmc/articles/PMC10028021/ /pubmed/36200595 http://dx.doi.org/10.1002/cam4.5319 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | RESEARCH ARTICLES Yao, Senbang Li, Wen Liu, Shaochun Cai, Yinlian Zhang, Qianqian Tang, Lingxue Yu, Sheng Jing, Yanyan Yin, Xiangxiang Cheng, Huaidong Aldehyde dehydrogenase 2 polymorphism is associated with chemotherapy‐related cognitive impairment in patients with breast cancer who receive chemotherapy |
title | Aldehyde dehydrogenase 2 polymorphism is associated with chemotherapy‐related cognitive impairment in patients with breast cancer who receive chemotherapy |
title_full | Aldehyde dehydrogenase 2 polymorphism is associated with chemotherapy‐related cognitive impairment in patients with breast cancer who receive chemotherapy |
title_fullStr | Aldehyde dehydrogenase 2 polymorphism is associated with chemotherapy‐related cognitive impairment in patients with breast cancer who receive chemotherapy |
title_full_unstemmed | Aldehyde dehydrogenase 2 polymorphism is associated with chemotherapy‐related cognitive impairment in patients with breast cancer who receive chemotherapy |
title_short | Aldehyde dehydrogenase 2 polymorphism is associated with chemotherapy‐related cognitive impairment in patients with breast cancer who receive chemotherapy |
title_sort | aldehyde dehydrogenase 2 polymorphism is associated with chemotherapy‐related cognitive impairment in patients with breast cancer who receive chemotherapy |
topic | RESEARCH ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028021/ https://www.ncbi.nlm.nih.gov/pubmed/36200595 http://dx.doi.org/10.1002/cam4.5319 |
work_keys_str_mv | AT yaosenbang aldehydedehydrogenase2polymorphismisassociatedwithchemotherapyrelatedcognitiveimpairmentinpatientswithbreastcancerwhoreceivechemotherapy AT liwen aldehydedehydrogenase2polymorphismisassociatedwithchemotherapyrelatedcognitiveimpairmentinpatientswithbreastcancerwhoreceivechemotherapy AT liushaochun aldehydedehydrogenase2polymorphismisassociatedwithchemotherapyrelatedcognitiveimpairmentinpatientswithbreastcancerwhoreceivechemotherapy AT caiyinlian aldehydedehydrogenase2polymorphismisassociatedwithchemotherapyrelatedcognitiveimpairmentinpatientswithbreastcancerwhoreceivechemotherapy AT zhangqianqian aldehydedehydrogenase2polymorphismisassociatedwithchemotherapyrelatedcognitiveimpairmentinpatientswithbreastcancerwhoreceivechemotherapy AT tanglingxue aldehydedehydrogenase2polymorphismisassociatedwithchemotherapyrelatedcognitiveimpairmentinpatientswithbreastcancerwhoreceivechemotherapy AT yusheng aldehydedehydrogenase2polymorphismisassociatedwithchemotherapyrelatedcognitiveimpairmentinpatientswithbreastcancerwhoreceivechemotherapy AT jingyanyan aldehydedehydrogenase2polymorphismisassociatedwithchemotherapyrelatedcognitiveimpairmentinpatientswithbreastcancerwhoreceivechemotherapy AT yinxiangxiang aldehydedehydrogenase2polymorphismisassociatedwithchemotherapyrelatedcognitiveimpairmentinpatientswithbreastcancerwhoreceivechemotherapy AT chenghuaidong aldehydedehydrogenase2polymorphismisassociatedwithchemotherapyrelatedcognitiveimpairmentinpatientswithbreastcancerwhoreceivechemotherapy |